Wall Street analysts expect that Menlo Therapeutics Inc (NASDAQ:MNLO) will announce earnings per share (EPS) of ($0.84) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Menlo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.81). Menlo Therapeutics posted earnings per share of ($0.36) during the same quarter last year, which would indicate a negative year-over-year growth rate of 133.3%. The business is scheduled to report its next quarterly earnings report on Wednesday, August 7th.
On average, analysts expect that Menlo Therapeutics will report full-year earnings of ($3.37) per share for the current year, with EPS estimates ranging from ($3.52) to ($3.19). For the next financial year, analysts forecast that the company will post earnings of ($2.46) per share, with EPS estimates ranging from ($2.87) to ($1.94). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Menlo Therapeutics.
Menlo Therapeutics (NASDAQ:MNLO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.81).
Shares of MNLO stock traded down $0.07 during trading hours on Friday, hitting $6.20. The stock had a trading volume of 22,138 shares, compared to its average volume of 32,961. The company has a market capitalization of $150.08 million, a P/E ratio of -2.62 and a beta of 2.98. Menlo Therapeutics has a twelve month low of $3.74 and a twelve month high of $12.00.
Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers purchased a new stake in Menlo Therapeutics during the 4th quarter worth approximately $48,000. State of Wisconsin Investment Board bought a new stake in shares of Menlo Therapeutics in the 1st quarter valued at approximately $100,000. Acadian Asset Management LLC bought a new stake in shares of Menlo Therapeutics in the 4th quarter valued at approximately $147,000. Bank of New York Mellon Corp increased its holdings in shares of Menlo Therapeutics by 51.0% in the 4th quarter. Bank of New York Mellon Corp now owns 38,662 shares of the company’s stock valued at $159,000 after acquiring an additional 13,064 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Menlo Therapeutics by 8.9% in the 4th quarter. Bank of America Corp DE now owns 42,160 shares of the company’s stock valued at $173,000 after acquiring an additional 3,448 shares during the last quarter. Institutional investors own 80.05% of the company’s stock.
Menlo Therapeutics Company Profile
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.